

This article was downloaded by: [Universitaets und Landesbibliothek]
On: 11 December 2013, At: 07:58
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH,
UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

Convenient Synthesis of 1-Oxa-3,8-diazaspiro [4,5] Decan-2-ones

R. Somanathan^a, I. A. Rivero^a, G. I. Nuñez^a & L. H. Hellberg^a

^a Centro de Graduados del Instituto Tecnológico de Tijuana, Apdo Postal 1166, Tijuana, B. C., MEXICO
Published online: 23 Sep 2006.

To cite this article: R. Somanathan, I. A. Rivero, G. I. Nuñez & L. H. Hellberg (1994) Convenient Synthesis of 1-Oxa-3,8-diazaspiro [4,5] Decan-2-ones, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 24:10, 1483-1487, DOI: [10.1080/00397919408011753](https://doi.org/10.1080/00397919408011753)

To link to this article: <http://dx.doi.org/10.1080/00397919408011753>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any

losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

**CONVENIENT SYNTHESIS OF 1-OXA-3,8-DIAZASPIRO
[4,5] DECAN-2-ONES.**

R. Somanathan*, I.A. Rivero, G.I. Nuñez and L.H. Hellberg.


Centro de Graduados del Instituto Tecnológico de Tijuana.
Apdo Postal 1166, Tijuana B. C. MEXICO.

ABSTRACT: Synthesis of 1-oxa-3,8-diazospiro [4,5] decan-2-ones from 4-pyridone by addition of trimethylsilyl cyanide.

Continuing our interest in the synthesis of new antihypertensive agents (1), the syntheses of 9-substituted-1-oxa -3,8-diazospiro [4,5]- decan-2-ones reported by Clark and co-workers (2,3) intrigued us. They are structurally related to the antihypertensive agent indoramine (4), a known post-synaptic α_1 adrenoceptor blocker. Our synthetic goal was to incorporate similar diazaspiro-[4,5]- decane-2-ones into molecules with the required quinazolinedione (1), and study their potential antihypertensive and other biological properties. Clark and co-workers had synthesized the diazospiro system starting from 1-benzyl-4-piperidone by addition of ethyllithioacetate followed by hydrazine and Curtius rearrangement to give an acylhydrazide, subsequent treatment of which with HNO_2 led to the diazospiro compound (3).

*To whom correspondence should be addressed

Here we wish to report a convenient alternative synthesis of the diazospiro system by adding trimethylsilyl cyanide to (1a) in the presence of catalytic amounts of zinc iodide to give the adduct (2) (7,8), which was reduced with LAH to give the amino alcohol (3), and subsequently ring closed with triphosgene to give the desired compound (4a) in 72% yield from (3). Using the same technique we also converted 1-(2-phenylethyl)-4-piperidone (1b) to Fenspiride (4b), a bronchodilator blocker (9,10).



EXPERIMENTAL

Melting points were obtained on a Gallenkamp apparatus and are uncorrected. Infrared spectra were recorded on a Perkin-Elmer FT-IR 1750 spectrophotometer. The proton nuclear magnetic resonance spectra were recorded on a Chemagnetic 200 MHz and Varian EM-390 90 MHz. Mass spectra were obtained on a Finnigan 3000 at 70 eV by direct insertion and data processed using the Teknivent system.

1-Benzyl-4-Cyano-4-Trimethylsilyloxipiperidone(2a):

Trimethylsilyl cyanide (2.66mL,0.019moles) was added dropwise to 1-benzyl-4-piperidone (3.32g,0.012moles) containing Zinc Iodide (\approx 50 mg) at 0°C. The mixture was stirred at 0°C for 3h and then heated at 60°C for additional 3h and the final product was distilled bulb-to-bulb using a Buchi-Kugelrohr oven at 165°C/4mmHg to give a clear liquid (4.65g, 91%). IR(KBr): 3090, 3060, 3020, 2960, 2810, 2760,1495,1250,1100, 870, 840 cm⁻¹. ¹H NMR (CDCl₃): δ 7.31 (s,5H, Ar-H), 3.50(s,2H,Ar-CH₂), 3.01-1.81(m,8H,CH₂), 0.24(s,9H, CH₃-Si)ppm. ¹³C NMR (CDCl₃): δ 175.17, 138.20, 128.80, 128.15, 127.03, 68.89, 62.44, 61.85, 49.38, 38.63,1.29 ppm. EM(m/e): 288(27), 260(23), 197(47), 91(100).

1-Benzyl-4-Aminomethyl-4-Piperidinol(3a):

LiAlH₄ (7mL,7.0mmoles in ether) was added dropwise to a stirred ice-cold solution of compound (2a) (1.54g, 5.3 mmoles) in ether (20mL). After 2h stirring, NaOH (20%) was added and the organic layer was decanted, the residue was further triturated with ether (30mL) and the combined organic phase was dried (Na₂SO₄) and removal of solvent gave a low melting solid (0.91g, 78%). mp. 72-73°C. IR(KBr): 3400, 3080, 3060 3030, 2930, 2810, 2760, 1600, 1450,1050, 970, 740, 690cm⁻¹. ¹H NMR (CDCl₃): δ 7.3(s,5H, Ar-H), 3.60(s,2H,Ar-CH₂), 3.58(s,1H,OH), 2.70-2.20 (m,10H,CH₂), 1.60(bs,2H, -NH₂)ppm. EM(m/e): 220(6), 190(26), 111(74), 91(100).

8-Benzyl-1-Oxa-2-Oxo-3.8-Diazospiro [4.5] Decane(4a):

Triphosgene (0.12g, 4.0mmoles) in dry dichlorometane (10mL) was added dropwise to a stirred solution of amino alcohol (3a) (0.99g, 4.1mmoles) in dichloromethane (25mL) at RT for 2h. The reaction was neutralized by addition of NaOH (1%, 20mL) and the organic layer was washed with water and dried (MgSO₄). Removal of solvent under reduced pressure gave a solid (0.801g, 72%). mp. 170-171°C. IR(KBr): 3290, 3020, 2920, 2800, 2760, 1750, 1700, 1440, 1250, 1150 cm⁻¹. ¹H NMR (CDCl₃): δ 7.20(s,5H, Ar-H), 5.80(bs,1H, NH) 3.60(s,2H,Ar-CH₂),

3.4(s,2H,CH₂-N-CO), 2.60(m,4H,CH₂-N), 1.90(m,4H,CH₂-) ppm. EM(m/e): 246(5), 245(3), 169(12), 155(24), 91(100). Analysis. Calcd. for C₁₄H₁₈O₂N₂: C,68.29; H, 7.31. Found: C, 68.48; H, 7.62 %.

The method described above were also used to synthesise compounds (2b), (3b) and (4b).

1-(2-Phenethyl)-4-Cyano-4-Trimethylsilyloxypiperidine(2b): bp. 165°C /4mmHg. IR(KBr): 3080, 3060, 3020, 2950, 2810, 2780, 2220, 1600, 1495, 1470, 1450, 1340, 1250, 1150, 1100, 870, 840 cm⁻¹. ¹H NMR (CDCl₃): δ 7.20 (m,5H, Ar-H), 2.96-1.83(m,12H,CH₂), 0.25(s,9H, CH₃-Si)ppm. EM(m/e): 287(4), 211(100), 112(12).

1-(2-Phenethyl)-4-aminomethyl-4-piperidinol(3b): IR(KBr):3440, 3080, 3060 3030, 2940, 2810, 1600, 1500,1460, 970, 740, 690 cm⁻¹. ¹H NMR (CDCl₃): δ 7.34 (m,5H, Ar-H), 2.86(m,14H,CH₂), 3.65(s,1H,OH), 1.58(bs,2H, -NH₂) ppm. EM(m/e): 234(6), 204(11), 144(83), 126(89), 112(62), 91(88), 77(90), 68(100).

8-(Phenethyl)-1-Oxa-2-Oxo-3,8-Diazospiro[4,5] Decane(4b): (1.087g, 69%). mp. 143-145°C. IR(KBr): 3260, 3020, 2920, 2810, 2760, 1740, 1490,1320, 1250, 1150,1090, 970, cm⁻¹. ¹H NMR (CDCl₃): δ 8.28(bs,1H,NH), 7.53-7.11(m,5H,Ar-H), 3.75-2.12(m,14H,CH₂) ppm. EM(m/e): 260(.1),169(100), 96(29). Analysis. Calcd. for C₁₅H₂₀O₂N₂: C, 69.23; H, 7.69. Found: C,67.27; H,7.47 %.

Acknowledgement: We gratefully acknowledge support of this project by CONACYT (GRANTS No. 1502-E9201 and 1528-E9207) and San Diego State University for Spectral Data.

REFERENCES:

- 1) R. Cortez, I.A. Rivero, R. Somanathan, G. Aguire, F. Ramirez and E. Hong, Synthetic Communications., **21**, 285 (1991).
- 2) R.D. Clark, J.M. Caroon, D.B. Repke, A.M. Strosberg, S.M. Bitter, M.D. Okada, A.D. Michel and R.L. Whiting, J. Med. Chem., **26**, 855 (1983).
- 3) J.M. Caroon, R. Clark, A.F. Kluge, J.T. Nelson, A.M. Strosberg, S.H. Unger, A.D. Michel and R.L. Whiting, J. Med. Chem., **24**, 21320 (1981).
- 4) J.L. Archibald, B.J. Alps, J.F. Cavalla and J.L. Jackson, J. Med. Chem., **14**, 1054 (1971).
- 5) D.A. Evans, G.L. Carroll and L.K. Truesdale, J. Org. Chem., **39**, 914 (1974).
- 6) R. Somanathan, H.R. Aguilar, G.R. Ventura and K.M. Smith, Synthetic Communications., **13**, 273 (1983).
- 7) Dutch Patent 6,504,602 (1965). CA, **64**, 12679d (1966).
- 8) The Organic Chemistry of Drug Synthesis, Vol. 2, pp.291 (1977) Eds. D. Lednicer and L.A. Mitscher, John Wiley & Sons, NY .

(Received in the USA 21 September 1993)